Both Fidaxomicin and Vancomycin Inhibit Outgrowth of Clostridium difficile Spores
- Additional Document Info
- View All
Fidaxomicin (FDX) is approved to treat Clostridium difficile-associated diarrhea and is superior to vancomycin in providing a sustained clinical response (cure without recurrence in the subsequent 25 days). The mechanism(s) behind the low recurrence rate of FDX-treated patients could be multifactorial. Here, we tested effects of FDX, its metabolite OP-1118, and vancomycin on spore germination and determined that none affected the initiation of spore germination but all inhibited outgrowth of vegetative cells from germinated spores.
author list (cited authors)
Allen, C. A., Babakhani, F., Sears, P., Nguyen, L. y., & Sorg, J. A.